EUCTR2016-004340-11-SEActive, not recruitingPhase 1
A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Bayer AG
- Enrollment
- 1,627
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Existence of archival or fresh biopsy for FGFR testing. Mandatory FGFR testing of patients will be performed prior to start of screening (signing of informed consent for study treatment eligibility). The timing of the FGFR test is at the discretion of the investigator. Investigators should ensure all patients will be eligible in terms of disease status and lines of treatment.
- •- Male or female patients = 18 years of age (at least age of legal maturity).
- •- Documented urothelial carcinoma (transitional cell carcinoma) including urinary bladder, renal pelvis, ureters, urethra, meeting all of the following criteria:
- •o Histologically confirmed. Patients with mixed histologies are required to have a dominant transitional cell pattern.
- •o Locally advanced (T4, any N; or any T, N 2-3) or metastatic disease (any T, any N and M1). Locally advanced bladder cancer must be unresectable i.e. invading the pelvic or abdominal wall (stage T4b) or presenting with bulky nodal disease (N2-3).
- •- ECOG Performance Status of 0 or 1.
- •- Disease progression during or following treatment with at least one platinum-containing regimen (patients should have been treated for at least 2 cycles). In patients who received prior adjuvant/neoadjuvant platinum-containing chemotherapy, progression had to occur within 12 months of treatment.
- •- High FGFR1 or 3 mRNA expression levels in archival or fresh tumor biopsy specimen quantified as outlined in the lab manual.
- •- At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST v.1.1) in contrast enhanced (unless contraindicated) CT or MRI
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 976
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 651
Exclusion Criteria
- •- Previous or concurrent cancer except
- •o cervical carcinoma in situ
- •o treated basal-cell or squamous cell skin carcinoma
- •o any cancer curatively treated > 3 years before randomization
- •o curatively treated incidental prostate cancer (T1/T2a)
- •- Ongoing or previous anti-cancer treatment within 4 weeks before randomization.
- •- More than two prior lines of systemic anti-cancer therapy for urothelial carcinoma given for advanced unresectable/metastatic disease.
- •- Ongoing or previous treatment with anti-FGFR directed therapies (e.g. receptor tyrosine kinase inhibitors including rogaratinib or FGFR-specific antibodies) or with taxanes or vinflunine
- •- Unresolved toxicity higher than National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 4.03 (CTCAE v.4.03) Grade 1 attributed to any prior therapy/procedure excluding alopecia, anemia and/or hypothyroidism.
- •- History or current condition of an uncontrolled cardiovascular disease including any of the following conditions:
- •o Congestive heart failure (CHF) NYHA > Class 2.
- •o Unstable angina (symptoms of angina at rest) or new-onset angina (within last 3 months before randomization).
- •o Myocardial infarction (MI) within past 6 months before randomization.
- •o Unstable cardiac arrhythmias requiring anti-arrhythmic therapy. Patients with arrhythmia under control with anti-arrhythmic therapy such as beta-blockers or digoxin are eligible.
- •- Arterial or venous thrombotic events or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before randomization.
- •- Current evidence of endocrine alteration of calcium phosphate homeostasis (e.g. parathyroid disorder, history of parathyroidectomy, tumor lysis, tumoral calcinosis, paraneoplastic hypercalcemia).
- •- Any hemorrhage / bleeding event = CTCAE v.4.03 Grade 3 within 4 weeks before randomization.
- •- Current diagnosis of any retinal detachment, retinal pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Phase 2/3 study of rogaratinib (pan FGFR inhibitor) vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma with a high amount of specific cell growth factor receptors 1 and 3 (FGFR1 and 3) in the tumor cellsmRNA FGF receptor 1 and 3 positive locally advanced or metastaticurothelial carcinoma progressed after prior platinum-containingchemotherapyMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2016-004340-11-DKBayer AG, D-51368 Leverkusen, Germany1,627
Active, not recruiting
Phase 1
Phase 2/3 study of rogaratinib (pan FGFR inhibitor) vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma with a high amount of specific cell growth factor receptors 1 and 3 (FGFR1 and 3) in the tumor cellsmRNA FGF receptor 1 and 3 positive locally advanced or metastaticurothelial carcinoma progressed after prior platinum-containingchemotherapyMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2016-004340-11-PTBayer AG, D-51368 Leverkusen, Germany175
Active, not recruiting
Phase 1
Phase 2/3 study of rogaratinib (pan FGFR inhibitor) vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma with a high amount of specific cell growth factor receptors 1 and 3 (FGFR1 and 3) in the tumor cells.mRNA FGF receptor 1 and 3 positive locally advanced or metastaticurothelial carcinoma progressed after prior platinum-containingchemotherapyMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2016-004340-11-CZBayer AG1,627
Active, not recruiting
Phase 1
Phase 2/3 study of rogaratinib (pan FGFR inhibitor) vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma with a high amount of specific cell growth factor receptors 1 and 3 (FGFR1 and 3) in the tumor cellsmRNA FGF receptor 1 and 3 positive locally advanced or metastaticurothelial carcinoma progressed after prior platinum-containingchemotherapyMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2016-004340-11-ATBayer AG, D-51368 Leverkusen, Germany1,627
Active, not recruiting
Phase 1
Phase 2/3 study of rogaratinib (pan FGFR inhibitor) vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma with a high amount of specific cell growth factor receptors 1 and 3 (FGFR1 and 3) in the tumor cellsEUCTR2016-004340-11-PLBayer AG1,627